Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating

Lucid Capital Markets initiated coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and a $5.50 price target, citing the company's KCC2 activator program as a potential source for transformative, first-in-class therapies addressing neurological disorders. This new target significantly exceeds the current analyst range, highlighting substantial upside for the $38.9 million market cap firm, which recently secured $7 million in non-dilutive funding and anticipates Phase 1 results for its OV329 program in Q3 2025.

Analysis

Lucid Capital Markets has initiated coverage on Ovid Therapeutics (OVID) with a 'Buy' rating and a $5.50 price target, an aggressive valuation that significantly exceeds the existing analyst consensus range of $1.50 to $4.00. This bullish outlook is underpinned by the potential of Ovid's KCC2 activator program, which targets a fundamental neurological mechanism and is positioned as a potential first-in-class therapy for a range of disorders including epilepsy. The company's financial position has been recently strengthened by a $7 million non-dilutive cash injection from the sale of future royalty rights for ganaxolone, providing capital for ongoing operations. While sentiment is positive, evidenced by a recent 7.21% stock gain and a 'Buy' rating from B.Riley ($3.00 target), there is a notable divergence in valuation perspectives, as H.C. Wainwright recently lowered its target to $1.50. The next major inflection point for the company is the anticipated readout of its Phase 1 study for the GABA-AT inhibitor OV329, with results expected in the third quarter of 2025.

Key Decisions for Investors

• Investors should view Ovid Therapeutics as a high-risk, speculative opportunity, where the new $5.50 price target reflects the long-term, transformative potential of its KCC2 platform rather than near-term fundamentals.
• The wide dispersion in analyst price targets, from $1.50 to $5.50, highlights significant valuation uncertainty and warrants careful position sizing.
• The primary catalyst to monitor is the Phase 1 clinical data for OV329 expected in Q3 2025, which will serve as a critical de-risking event for the pipeline.
• While the recent $7 million in non-dilutive funding improves the company's balance sheet, investors should closely track cash burn to ensure sufficient runway through key clinical milestones.